Network meta-analysis for deaths_(OS)

Network meta-analysis estimations pool direct and indirect evidences. These results should be considered as exploratory given the absence of assessment of transitivity assumption plausibility. Calculations by netmeta package.

T vs. C	Standard of Care (SoC)	placebo plus SoC	atezolizumab plus nab-paclitaxel	atezolizumab plus paclitaxel	pembrolizumab plus SoC	capivasertib plus paclitaxel	ipatasertib plus paclitaxel	veliparib plus paclitaxel plus carboplatin
Standard of Care (SoC)	---	NA	1.23 1.06; 1.42	0.90 0.73; 1.10	1.18 1.05; 1.31	1.78 1.13; 2.79	1.25 0.78; 2.00	1.22 0.72; 2.07
placebo plus SoC	NA	---	NA	NA	NA	NA	NA	NA
atezolizumab plus nab-paclitaxel	0.81 0.70; 0.94	NA	---	0.73 0.57; 0.94	0.96 0.80; 1.15	1.45 0.90; 2.33	1.02 0.62; 1.67	0.99 0.57; 1.72
atezolizumab plus paclitaxel	1.12 0.91; 1.37	NA	1.37 1.07; 1.77	---	1.31 1.04; 1.66	1.99 1.21; 3.26	1.40 0.84; 2.33	1.36 0.77; 2.40
pembrolizumab plus SoC	0.85 0.76; 0.95	NA	1.04 0.87; 1.26	0.76 0.60; 0.96	---	1.51 0.95; 2.41	1.06 0.66; 1.72	1.04 0.60; 1.78
capivasertib plus paclitaxel	0.56 0.36; 0.88	NA	0.69 0.43; 1.11	0.50 0.31; 0.83	0.66 0.42; 1.05	---	0.70 0.37; 1.35	0.69 0.34; 1.37
ipatasertib plus paclitaxel	0.80 0.50; 1.28	NA	0.98 0.60; 1.61	0.72 0.43; 1.20	0.94 0.58; 1.52	1.42 0.74; 2.73	---	0.98 0.48; 1.98
veliparib plus paclitaxel plus carboplatin	0.82 0.48; 1.39	NA	1.01 0.58; 1.74	0.73 0.42; 1.29	0.96 0.56; 1.65	1.46 0.73; 2.92	1.02 0.51; 2.08	---

pathologies: 269,60,143 - treatments: 1252 result logic